Associations of plasma protein levels with risk of colorectal cancer: a proteome-wide Mendelian randomization study.

Background: The treatment of advanced or metastatic colorectal cancer (CRC) poses a global challenge. Mendelian Randomization (MR) has been primarily applied for repurposing licensed drugs and uncovering new therapeutic targets.

Objective: This study aims to systematically identify potential plasma protein targets for CRC using proteome-wide Mendelian randomization and evaluate their potential side effects through phenome-wide association studies (Phe-WAS).